ALG-055009 ALG-055009, a potent, selective THR-β agonist for treatment of NASH, demonstrates significant cholesterol reduction in a Diet-Induced Obese (DIO) mouse efficacy model
ALG-000184, Publications Best-in-class preclinical characteristics of ALG-000184, a prodrug of the capsid assembly modulator ALG-001075 for the treatment of chronic hepatitis B
ALG-055009, Publications Characterization of thyroid hormone receptor agonists for the treatment of NASH by quantification of gene transcription in human hepatocytes
Preclinical, Publications Tumor regression in a mouse model of hepatocellular carcinoma upon treatment with the STING agonist ALG-031048
Publication, Publications Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
ALG-000184, Publications ALG-000184, a prodrug of capsid assembly modulator ALG-001075, demonstrates best-in-class preclinical characteristics for the treatment of chronic hepatitis B
ALG-055009, Publications Molecular, cellular and pharmacological characterization of beta selective partial agonists of human thyroid hormone receptor for the treatment of nonalcoholic steatohepatitis
ALG-055009, Publications Preclinical Development of ALG-055009 as a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of NASH
Preclinical, Publications Preclinical Assessment of Potency and Efficacy of a Novel Class-II Capsid Assembly Modulator, ALG-001024